|
1) Morioka J, Fujii M, Kato S, et al. Surgery for spontaneous intracerebral hemorrhage has greater remedial value than conservative therapy. Surg Neurol. 2006; 65: 67-72
|
|
|
|
2) 嶋 緑倫, 吉岡 章. 凝固第VIII因子インヒビター. 血液腫瘍科. 1994; 28: 404-12
|
|
|
|
|
|
3) 新井盛夫. 凝固因子自己抗体による出血傾向: 病態の概要と臨床検査診断の留意点. 臨床病理. 2004; 52: 178-81
|
|
|
|
|
4) 嶋 緑倫, 川合陽子, 辻 肇, 他. 本邦における血液凝固後天性インヒビターの実態. 日本血栓止血学会誌. 2003; 14: 107-21
|
|
|
|
|
|
5) Laguna P, Klukowska A. Intracranial haemorrhage in a boy with severe haemophilia A and factor VIII inhibitor. Child Nerv Syst. 2006; 22: 432- 5
|
|
|
|
|
|
6) Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Hemostasis. 1998; 28: 93-8
|
|
|
|
|
|
7) Schmidt ML, Gamerman S, Smith HE, et al. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol. 1994; 47: 36-40
|
|
|
|
|
|
8) Majumdar G, Savidge GF. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis. 1993; 4: 1031-3
|
|
|
|
|
|
9) Mikami T, Masauzi N, Niwa J, et al. Acquired factor VIII inhibitors in a patient associated with neurosurgery: case report and review of the literature. Neurosurgery. 2005; 57: 595
|
|
|
|
|
|
10) Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thrombo Haemost. 1997; 78: 1463-7
|
|
|
|
|
|
11) 松浦康弘, 青墳信之, 脇田 久. 当院における後天性血友病(血友病に伴わない後天性凝固第VIII因子インヒビター)4例の治療経験. 診療と新薬. 2005; 42: 159-67
|
|
|
|
|
|
12) Libman RB, Lungu C, Kwiatkowski T. Multiple ischemic strokes associated with use of recombinant activated factor VII. Arch Neurol. 2007; 64: 879-81
|
|
|
|
|
|
13) Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Heamost. 2004; 2: 899-909
|
|
|
|
|
|
14) Mayer SA, Brun NC, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care. 2006; 4: 206-14
|
|
|
|
|
|
15) Mayer SA. Recombinant activated factor VII for acute intracerebral hemorrhage. Stroke. 2007; 38(2 Suppl): 763-7
|
|
|
|
|
|
16) Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006; 59: 767-73
|
|
|
|
|
|
17) Diringer MN, Ferran JM, Broderick J, et al. Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage. Cerebrovasc Dis. 2007; 28: 219-25
|
|
|
|
|
|
18) Earnshaw SR, Joshi AV, Wilson MR, et al. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006; 37: 2751-8
|
|
|
|
|
|
19) Nadeau JO, Phillips S, Shi HS, et al. Intracerebral hemorrhage: outcomes and eligibility for factor VIIa treatment in a National Stroke Registry. Cerebrovasc Dis. 2006; 22: 271-5
|
|
|
|
|
|
20) Kumar S, Badrinath HR. Early recombinant factor VIIa therapy in acute intracerebral hemorrhage: promising approach. Neurol India. 2006; 54: 24-7
|
|
|
|
|